key: cord-0897497-tmmxmgb4
authors: Chen, Chen; Wang, Feng; Chen, Peng; Jiang, Jiangang; Cui, Guanglin; Zhou, Ning; Moroni, Francesco; Moslehi, Javid J.; Ammirati, Enrico; Wang, Dao Wen
title: Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients
date: 2020-10-29
journal: J Am Heart Assoc
DOI: 10.1161/jaha.120.017736
sha: eb043f917ac408a8e3549db08ac00d7fce3ad93b
doc_id: 897497
cord_uid: tmmxmgb4

BACKGROUND: There has been significant controversy regarding the effects of pre‐hospitalization use of renin‐angiotensin system (RAS) inhibitors on the prognosis of hypertensive COVID‐19 patients. METHODS AND RESULTS: We retrospectively assessed 2,297 hospitalized COVID‐19 patients at Tongji Hospital in Wuhan, China, from January 10(th) to March 30(th), 2020; and identified 1,182 patients with known hypertension on pre‐hospitalization therapy. We compared the baseline characteristics and in‐hospital mortality between hypertensive patients taking RAS inhibitors (N=355) versus non‐RAS inhibitors (N=827). Of the 1,182 hypertensive patients (median age 68 years, 49.1% male), 12/355 (3.4%) patients died in the RAS inhibitors group vs. 95/827 (11.5%) patients in the non‐RAS inhibitors group (p<0.0001). Adjusted hazard ratio for mortality was 0.28 (95% CI 0.15‐0.52, p<0.0001) at 45 days in the RAS inhibitors group compared with non‐RAS inhibitors group. Similar findings were observed when patients taking angiotensin receptor blockers (N=289) or angiotensin converting enzyme inhibitors (N=66) were separately compared with non‐RAS inhibitors group. The RAS inhibitors group compared with non‐RAS inhibitors group had lower levels of C‐reactive protein (median 13.5 vs. 24.4 pg/mL; p=0.007) and interleukin‐6 (median 6.0 vs. 8.5 pg/mL; p=0.026) on admission. The protective effect of RAS inhibitors on mortality was confirmed in a meta‐analysis of published data when our data were added to previous studies (odd ratio 0.44, 95% CI 0.29–0.65, p<0.0001). CONCLUSIONS: In a large single center retrospective analysis we observed a protective effect of pre‐hospitalization use of RAS inhibitors on mortality in hypertensive COVID‐19 patients; which might be associated with reduced inflammatory response.

Definitive data on the safety or potential benefit of RAS inhibitors are of paramount importance due to the severity of COVID-19 especially in hypertensive patients. Thus, we further investigated the association between RAS inhibitors and mortality in a large single-center retrospective study including hospitalized COVID-19 patients at Tongji Hospital in Wuhan, China. We also reported the association with mortality analyzing separately patients taking ACEi and ARB.

This article is protected by copyright. All rights reserved

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The study was approved by the Ethics Review Board of Tongji Hospital and Tongji Medical College (IRB ID: TJ-IRB20200229) and conformed to the principles of the Declaration of Helsinki. The requirement for written informed consent was waived by the Ethics committee because of the retrospective and anonymous nature of the data, collected during an emerging infectious disease as reported in other hospitals in Wuhan. 23 A total of 2,297 patients with COVID-19 admitted from January 10 th to March 30 th , 2020, were enrolled in the current study. The clinical follow-up was terminated on April 24 th , 2020, when the last COVID-19 patient was discharged. Thus, all patients were followed up to in-hospital death or discharge. The diagnosis of COVID-19 was based on symptoms, positive real-time polymerase chain reaction for SARS-CoV-2 on nasopharyngeal swab and radiological findings of interstitial pneumonia on computed tomography (CT) scan. Accordingly to the Guidance for Corona Virus Disease 2019 (5th edition) released by the National Health Commission of China 1, 24 , hospitalized patients included in the analysis had moderate (symptoms plus radiological confirmed pneumonia), severe (presenting with shortness of breath, respiratory rate [RR]≥30 counts/min, oxygen saturation <93% at rest or the ratio between arterial partial pressure of oxygen and fraction of inspired oxygen ≤300mmHg), or critical disease (requiring IMV, in shock or multiorgan failure).

All clinical data were extracted from patients' electronic medical records and were carefully checked by two experienced physicians (C.C and F.W.). Personal information, medical history, and coexisting comorbidities included chronic heart disease (CHD) including coronary artery disease and chronic heart failure, diabetes, and chronic kidney disease (CKD) were self-reported or evaluated by the attending physician on admission. CKD was diagnosed on admission if estimated glomerular filtration rate was <60 mL/min/1.73 m 2 . Vital signs, symptoms, laboratory test, and radiological findings were recorded on admission.

This article is protected by copyright. All rights reserved

The Kolmogorov-Smirnov test was performed to determine the distribution of continuous data.

Continuous values were shown as mean ± standard deviation (SD) if normally distributed, or medians and first to third quartile (Q1-Q3) if not normally distributed. Student's t test was used to compare the differences in normally distributed continuous values, Mann Whitney test was used to evaluate the differences in non-normal distributed continuous values. Categorical variables were described as counts and percentages, χ2 test and Fisher test were used to evaluate the differences in categorical variables, as appropriate. These tests were used to compare baseline characteristics between hypertensive patients (N=1,267) vs. non-hypertensive patients (N=1,019), RAS inhibitors group (N=355) vs. non-RAS inhibitors group (N=827), and finally patients on ARB (N=289) vs.

non-RAS inhibitors group, and patients on ACEi (N=66) vs. non-RAS inhibitors group.

The association between RAS inhibitors group vs. non-RAS inhibitors group, and between ARBs and ACEi vs. non-RAS inhibitors group and in-hospital mortality was evaluated by Kaplan-Meier (KM) survival curves and the log-rank test. Adjusted hazard ratios (HR) and 95% confidence interval (CI) were determined by multivariable Cox proportional hazards regression analyses. The proportional-hazards assumption was examined by including an interaction term between the group and log-transformed follow-up time, and extended Cox models where group was included as a time-varying covariate was used if a violation of the proportional-hazards assumption. The covariates of age, sex, history of CHD, diabetes mellitus, creatinine levels, use of calcium channel blockers, beta-blockers, diuretics, antidiabetic drugs and lipid lowering drugs were used at 30 and 45 days of follow up. All statistical analyses were performed using SPSS 21.0 software. Methods regarding systematic review and metanalysis (Table S1 ) are reported in Data S1.

We identified 1,278 COVID-19 patients who carried a diagnosis of hypertension on admission, representing 55.6% of all admitted patients, and 1,019 normotensive COVID-19 patients. Among hypertensive COVID-19 patients, 1,182 (92.5%) patients were taking at least one antihypertensive drug on admission, which was continued during hospitalization, whereas in 11 (0.9%) patients, antihypertensive therapy was stopped, and another 85 (6.7%) patients were diagnosed with hypertension by the attending physician on admission. To assess the role that antihypertensives may play in the prognosis of COVID-19, we focused on 1,182 patients with hypertension diagnosis prior to admission on antihypertensive medications before admission. We assessed

This article is protected by copyright. All rights reserved whether ACE inhibitors or ARB preferentially accounted for the improved prognosis by comparing patients taking ARB and patients taking ACEi (RAS inhibitors group, N=355, 30.0%) to non-RAS inhibitors group (N=827, 70.0%) ( Figure S1 ).

Clinical characteristics and outcomes of hypertensive vs. non-hypertensive COVID-19 patients As shown in Table 1 , the median age of patients with hypertension was significantly higher than patients without hypertension (median 67 vs. 54 years, p<0.0001), while the proportion of male were 49.5% vs. 45.4% (p=0.054). Overall, the hypertensive patients had an increased cardiovascular risk profile with a higher body mass index (BMI), and a greater prevalence of CHD, diabetes and CKD. On chest CT there were more severe radiological findings, such as lung consolidations in hypertensive patients. On laboratory tests there was an increase of markers of cardiac injury such as high sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro-B type natriuretic peptide (NT-proBNP) and inflammatory markers, such as C-reactive protein (CRP) (median 21.5 vs. 6.8 pg/mL; p<0.0001) and interleukin (IL)-6 (median 8.0 vs. 3.2 pg/mL; p<0.0001) in hypertensive patients compared non-hypertensive patients. The outcomes of hypertensive patients were worse compared to non-hypertensive patients, both in term of in-hospital mortality (10.2% vs. 5 .4% in hypertensive vs. non-hypertensive patients, p<0.0001, Table 1 ), and other complications such as need for IMV, multiorgan dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), septic shock, acute myocardial infarction (AMI), congestive heart failure, and cerebral hemorrhage.

In Table 2 clinical characteristics of hypertensive COVID-19 patients taking anti-hypertensive drugs before hospitalization are reported. When comparing RAS inhibitors vs. non-RAS inhibitors group, the RAS inhibitors group had similar median age (68 vs. 68 years, p=0.73) and proportion of male (49.6% vs. 48.9%, p=0.82). The RAS inhibitors group had a higher prevalence of CHD (24.5% vs. 14.4% in non-RAS inhibitors group, p<0.0001), while the BMI, and prevalence of diabetes and CKD was similar compared to non-RAS inhibitors group. There were no significant differences in the proportion of radiological abnormal findings on chest CT and some laboratory findings in RAS inhibitors compared to non-RAS inhibitors group, including hs-cTnI levels (8.6 Accepted Article vs. 7.5 pg/mL in RAS vs. non-RAS inhibitors group; p=0.84), pg/mL in RAS vs. non-RAS inhibitors group; p=0.59). However, RAS inhibitors compared to non-RAS inhibitors group had a significantly reduced levels of inflammatory markers (CRP: 13.5 vs. 24.4 pg/mL; p=0.007; IL-6: 6.0 vs. 8.5 pg/mL; p=0.026, compared to non-RAS inhibitors group) and d-dimer (0.76 vs. 1.05 μg/mL, p=0.0003 compared to non-RAS inhibitors group).

Importantly, RAS inhibitors group had more favorable prognosis compared to non-RAS inhibitors group, both in terms of in-hospital mortality (3.4% vs. 11 .5% in hypertensive vs. non-hypertensive patients, p<0.0001; Table 2 ), and other complications such as need for IMV (11.3% vs. 16.8%, p=0 .015), disseminated intravascular coagulation (DIC, 0.0% vs. 1.6%, p=0.018) and cerebral hemorrhage (0.3% vs. 1.7%, p=0.047) in RAS inhibitors group vs. non-RAS inhibitors group.

When the HR for mortality was adjusted, RAS inhibitors vs. non-RAS inhibitors group still showed a reduced mortality both at 30 days (HR 0.28; 95% CI 0.15-0.53, p<0.0001) and 45 days (HR 0.28; 95% CI 0.15-0.52, p<0.0001) of follow ( Figure 1A-B) .

Finally, we did not observe differences in the relative proportion of immediate causes of death between hypertensive COVID-19 patients taking RAS inhibitors vs. patients with non-RAS inhibitors. Specifically, most of deaths were related to COVID-19 pneumonia ( Table 3) .

As shown in Table 4 , patients on ARB vs. non-RAS inhibitors group had similar median age (68 vs. 68 years, p=0.86), and proportion of male (47.1% vs. 48.9%, p=0.60). The ARB group had a higher prevalence of CHD (23.2% vs. 14.4% in non-RAS inhibitors group, p=0.0005), while the BMI, and prevalence of diabetes and CKD was similar compared to non-RAS inhibitors group. On chest CT there was no significant difference in the proportion of radiological findings in ARB vs.

non-RAS inhibitors group. Likewise, laboratory tests showed no difference in the majority of results, including hs-cTnI levels or creatinine levels; however, ARB group showed reduced levels of inflammatory markers (CRP: 11.8 vs. 24.4 pg/mL; p=0.006; IL-6: 6.0 vs. 8.5 pg/mL; p=0.017, and tumor-necrosis factor [TNF]-α 8.4 vs. 8.8 pg/mL, p=0.038 compared to non-RAS inhibitors group) and d-dimer (0.73 vs. 1.05 μg/mL, p=0.0001 compared to non-RAS inhibitors group). The outcomes of ARB group were more favorable compared to non-RAS inhibitors group, in term of in-hospital mortality (3.1% vs. 11 .5% compared to non-RAS inhibitors group, p<0.0001; Table   4 ), as well as the need for IMV (9.0% vs. 16.8%, p=0.001), and DIC (0.0% vs. 1.6%, p=0.027).

This article is protected by copyright. All rights reserved When the HR for mortality was adjusted, ARB group vs. non-RAS inhibitors group still showed a reduced mortality both at 30 days (HR 0.26; 95% CI 0.13-0.55, p=0.0004) and 45 days (HR 0.28; 95% CI 0.14-0.55, p=0.0003) of follow ( Figure 1C-D) .

Finally, patients on ACEi vs. non-RAS inhibitors group had similar median age (65 vs. 68 years, p=0.18) with a trend for a higher proportion of male (60.6% vs. 48.9%, p=0.066) respectively ( Table 4 ). The ACEi group had a higher prevalence of CHD (30.3% vs. 14.4% in non-RAS inhibitors group, p=0.0006), while the prevalence of diabetes and CKD was similar compared to non-RAS inhibitors group. On chest CT there was a higher prevalence of patch shadow lesions (89.4% vs. 73.2%, p=0.004) vs. non-RAS inhibitors group. On laboratory tests there was a significant increase of creatinine levels (77 vs. 70 mmol/L, p=0.024), and markers of cardiac injury such as hs-cTnI (11.7 vs. 7.5 pg/mL, p=0.047) in ACEi group vs. non-RAS inhibitors group, while no significant differences were observed in the levels of inflammatory markers and d-dimer. There was a trend for reduced mortality in the ACEi group compared to non-RAS inhibitors group (4.6% vs. 11.5%, p=0.082; Table 4 ), while a higher proportion of AMI (6.1% vs.

1.5%, p=0.025) and congestive heart failure (10.6% vs. 4.1%, p=0.026) were observed in the ACEi group vs. non-RAS inhibitors group. When the HR for mortality was adjusted, ACEi group vs. non-RAS inhibitors showed a trend at 30 days (HR 0.32; 95% CI 0.10-1.01, p=0.053), and a significant reduction in mortality at 45 days (HR 0.30; 95% CI 0.09-0.95, p=0.041) of follow up ( Figure 1E -F).

Literature search identified 393 studies. Amongst these, 380 were excluded during screening based on title and abstract. Of the 13 remaining studies, 8 were excluded at a second verification phase ( Figure S2 ) and 5 observational, retrospective studies including a total of 1,658 hypertensive COVID-19 patients were included in the analysis. 1, 3, [20] [21] [22] Four-hundred thirty-one out of 1,754 subjects were treated with RAS inhibitors, which yielded a pooled rate of 38.3% (95% CI 21.4-55.3%). When data from the present work were included, the total number of patients rose to 2,936. Among these subjects, 786 were on RAS inhibitors, for a pooled rate of RAS inhibitors use of 36.5% (95% CI 25.41-47.7%). The use of RAS inhibitors was associated with a reduced risk of COVID-19 associated mortality when only previously published papers were analyzed (odds ratio

[OR] 0.54, 95% CI 0.37-0.79; p=0.002; Figure 2A ). Low heterogeneity was evident for this analysis (I 2 =0%). The protective effect of RAS inhibitors with respect to mortality was reinforced

This article is protected by copyright. All rights reserved when data from the present work were also included (OR 0.44, 95% CI 0.29-0.65; p<0.0001; Figure 2B ). Moderate heterogeneity was present for this analysis (I 2 =27%).

In this large single-center study, hypertensive patients on RAS inhibitors prior to hospitalization showed a significantly lower in-hospital mortality (3.4%) compared to patients non-taking RAS inhibitors (11.5%), despite the RAS inhibitors group having a higher prevalence of CHD. After adjustment for age, sex, pre-existing conditions and concurrent medications, pre-hospitalization use of RAS inhibitors still showed a significant decreased HR for mortality at 45 days. Of interest, patients on RAS inhibitors on admission presented with reduced markers of inflammation, and coagulation that have been previously associated with favorable prognosis. 5 Pre-hospitalization use of RAS-inhibitors was also associated with reduced need for IMV, lower proportion of DIC and cerebral hemorrhage. Given the large number of patients taking RAS inhibitors in our study, we performed sub-analyses on patients taking ARB or ACEi and observed a similar beneficial effect on mortality at 45 days on patients taking either drug. This protective effect was less pronounced in the ACEi group although this could be due to lower number of patients being on ACEi compared to ARB. Finally, a meta-analysis, juxtaposing our results with previous studies, support the potential beneficial effects of pre-hospitalization use of RAS inhibitors on prognosis of hypertensive COVID-19 patients. 1, 3, 21, 22 Most data on the association between the use of RAS inhibitors and mortality in hypertensive COVID-19 patients are derived from hospitals in Wuhan, China ( Figure 2C) . Specifically, a multicenter study coordinated by the Renmin hospital showed in-hospital mortality of 3.7% in the RAS inhibitors group vs. 9.8% in non-RAS inhibitors group, that was very closed to our findings. 1 The results by Zhang et al. held true after propensity score-matched analysis. 1 Here we utilize the larger number patients in our cohort (almost twice the number of patients on RAS inhibitors compared to the previous study) to further assess the individual benefit from ACEi and ARB. The previous study by Zhang et al. 1 was based on 188 patients on ACEi/ARB, of which only 31 on ACEi, with data being derived from nine hospitals increasing the variability of the outcome related to the different recruiting sites. Still, other studies that have been done assessing the baseline risk of RAS inhibitors on hypertensive COVID-19 patients included even small number of patients (range of 17-115 patients on RAS inhibitors depending on the study). 3, 21, 22 Partial confirmation of our findings is also derived by a multicenter international registry that reported an independent

This article is protected by copyright. All rights reserved survival benefit among patients taking ACEi, but not with ARB, even if that study was not aimed to compare specifically ACEi or ABR versus non-RAS inhibitors in hypertensive COVID-19 patients. 6 Another interesting study from New York that investigated the association among five classes of anti-hypertensive drugs (ACEi, ARB, beta-blockers, calcium-channel blockers and thiazide diuretic) with the risk of IMV, admission in ICU or mortality found that calcium channel blockers were significantly associated with this combined outcome (OR of 1.24, p=0.04) in a multivariate logistic regression analysis after adjustment for demographic and comorbidities. 17 ACEi and ARB were not associated with this combined outcome. Potential explanations for different results can be the following: (1) in our study, the combination of antihypertensive drugs and the use of calcium channel blockers (up to 81.3% vs. 36.2%, respectively) were more frequently used compared to the study by Reynolds et al., 17 (2) there were also different demographic characteristics (significantly increased BMI and higher racial diversity in the New Yorker cohort), and proportion of comorbidities (greater proportion of patients with CHD, CKD, and diabetes in the New Yorker cohort).

To further provide hypotheses for the protective effects of RAS inhibitors, we assessed biomarkers of inflammation and coagulation in our patients. We observed that patients taking RAS inhibitors have decreased levels of CRP, IL-6, and D-dimer, makers of inflammation and coagulation that have been associated with prognosis in COVID-19 patients. 5, 7 It must be noted that in our hypertensive population these inflammatory markers as well as d-dimer were significantly increased compared to non-hypertensive patients; in addition, mortality was significantly higher.

Even if we cannot completely rule out that the lower inflammatory response in patients with RAS inhibitors in this retrospective analysis might be due to their relatively modest symptoms and organ damage compared to non-RAS inhibitors group. Still, further research is needed, and other possible hypotheses could account for the protection conferred by RAS inhibitors. It is possible that chronic use of RAS inhibitors decreases the levels of angiotensin II, leading to lower the expression of ACE2 on type II pneumocytes, decreasing viral entry and viral load. 10 A decreased viral load at the interface between alveoli and bloodstream could curtail the inflammatory and coagulative responses often observed in COVID-19 patients leading to severe clinical manifestations. 5, 7 However, human data are lacking regarding the effects of RAS inhibitors on lung-specific expression of ACE2, 10 and our retrospective study cannot provide any evidence on changes in ACE2 expression in the lungs. It is also possible that hypertensive patients have higher levels of angiotensin II compared with non-hypertensive, leading to increased levels of ACE2,

This article is protected by copyright. All rights reserved potentially explaining a higher viral load in the lungs as trigger of a more florid inflammatory response and associated lung injury. Of note, patients in our cohort were taking RAS inhibitors, and they did not start these medications on admission. Thus, we cannot interfere that an acute administration of an ACEi or ARB can lead results observed in the present study. A trial of losartan among COVID-19 patients who have not previously received a RAS inhibitor and are hospitalized will try addressing this issue (NCT04312009). 10 A major limitation of our study is its observational and retrospective nature. In addition, the impact of combination of antihypertensive therapies cannot completely be controlled for even after multivariate adjustment. However, we were able to account potential changes in hypertensive treatment during hospitalization. Only in 11 patients were anti-hypertensive therapies stopped on admission. We excluded such patients in our analysis. Nevertheless, our study is the largest study to date to assess pre-hospitalization use of RAS inhibitors on prognosis in hypertensive COVID-19 patients.

In conclusion, in this large single center retrospective study, we reported a protective effect of pre-hospitalization use of RAS inhibitors on mortality compared with hypertensive COVID-19 patients non-taking RAS inhibitors. This observation holds true after multivariate adjustments and considering either the chronic use of ARB or ACEi compared with non-RAS inhibitors group.

RAS inhibitors were associated with reduced inflammatory and coagulation markers, suggesting an explanation to mortality reduction. The clinical impact of the current finding is relevant. In fact, it can further reassure hypertensive patients on RAS inhibitors that they are not at increased risk of mortality if infected by SARS-CoV-2 compared with patients taking other classes of antihypertensive drugs. 10 Finally, these results can open the debate if RAS inhibitors can be the drugs of choice for hypertensive patients during the COVID-19 pandemic, even if RAS inhibitors cannot be interpreted as COVID-19 treatment based on these retrospective analyses. Hb (g/dL) 12.7 (11.5-13.8) 12.8 (11.7-14.0) 12.6 (11.4-13.6 

BMI indicates body mass index; CHD, chronic heart disease; CKD, chronic kidney disease; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell;

Neut, neutrophil; Lymph, lymphocyte; Hb, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; TC, total cholesterol; LDL, low-density lipoprotein; K + , potassium; Glu, glucose; CK-MB, creatine kinase-MB; hs-cTnI, highly sensitive cardiac troponin I;

NT-proBNP, N-terminal pro-natriuretic peptide; hs-CRP, highly sensitive C reaction protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; TNF-α, tumor necrosis factor-α; IMV, invasive mechanical ventilation; MODS, multiple organ dysfunction syndrome; ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; AMI, acute myocardial infarction. LDL are shown as mean ± SD, other data are shown as median (first to third quartile, Q1-Q3). Laboratory data, median (Q1-Q3) or mean ± SD WBC (*10 9 /L) 6.00 (4.78-7.84) 6.13 (4.82-7.80) 5.97 (4.75-7.99) 0.5389 Neut (*10 9 /L) 4.17 (2.98-5.95) 4.12 (2.99-5.68) 4.18 (2.96-5. Hb (g/dL) 12.5 (11.4-13.6) 12.7 (11.3-13.7) 125 (11.4-13.6) 

This article is protected by copyright. All rights reserved BMI, body mass index; CHD, chronic heart disease; CKD, chronic kidney disease; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; Neut, neutrophil; Lymph, lymphocyte; Hb, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; TC, total cholesterol; LDL, low-density lipoprotein; K + , potassium; Glu, glucose; CK-MB, creatine kinase-MB; hs-cTnI, highly sensitive cardiac troponin I; NT-proBNP, N-terminal pro-natriuretic peptide; hs-CRP, highly sensitive C reaction protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; TNF-α, tumor necrosis factor-α; IMV, invasive mechanical ventilation; MODS, multiple organ dysfunction syndrome; ARDS, acute respiratory distress syndrome;

DIC, disseminated intravascular coagulation; AMI, acute myocardial infarction.

SBP and K + are shown as mean ± SD, other data are shown as median (first to third quartile, Q1-Q3).

Comparisons between hypertensive COVID-19 patients treated with ARB group and ACEi group were indicated as *P﹤0.05, **P﹤0.01, $ P﹤0.001, and & P﹤0.0001.

This article is protected by copyright. All rights reserved 

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Clinical Characteristics of Coronavirus Disease 2019 in China

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Accepted Article This article is protected by copyright. All rights reserved

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology

ESC/ESH Guidelines for the management of arterial hypertension

Aldosterone System Inhibitors in Patients with Covid-19

COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA : the journal of the

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Accepted Article This article is protected by copyright. All rights reserved Clinically Proven Protease Inhibitor

Angiotensin-converting enzyme 2 is an essential regulator of heart function

SARS-CoV-2 and viral sepsis: observations and hypotheses

Association of Use of Angiotensin-Converting Enzyme Inhibitors and

Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. The New England journal of medicine

RAAs inhibitors and outcome in patients with SARS-CoV-2 pneumonia. A case series study

Effects of angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and yypertension: A single-center retrospective study

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

chronic kidney disease; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell

Cr, creatinine; TC, total cholesterol; LDL, low-density lipoprotein

creatine kinase-MB; hs-cTnI, highly sensitive cardiac troponin I; NT-proBNP, N-terminal pro-natriuretic peptide; hs-CRP, highly sensitive C reaction protein; ESR, erythrocyte sedimentation rate

ARB, angiotensin receptor blockers

CCB, calcium channel blockers; IMV, invasive mechanical ventilation

MODS, multiple organ dysfunction syndrome

ARDS, acute respiratory distress syndrome

acute myocardial infarction. SBP and K + are shown as mean ± SD, other data are shown as median

Myocardial injury, median

Inflammatory factors, median

ACEi" and "ARB". Detailed queries can be found in Table S1. All published articles reporting mortality data among hypertensive COVID-19 patients on RAS inhibitors vs not treated with RAS inhibitors were included in the analysis. Two investigators (F.M., E.A.) independently extracted data on study design, patient characteristics and outcomes using pre-specified forms

Cumulative event rates for the relevant endpoints were calculated. A randomeffects model meta-analysis was performed with the Mantel-Haenszel method to calculate the pooled estimate rates and 95%CI of study outcomes. Statistical significance was set at p-value <0.05 (twosided) and with a 95% CI not crossing 1.00. To assess heterogeneity across studies, we used Cochrane Q-statistic to compute I2 values: <25%, 25-50%, or >50% indicated low, moderate, or high heterogeneity, respectively. Sensitivity analysis including original data from the present work was performed to thoroughly summarize available evidence. Statistical analyses were conducted with Review Manager

We thank all our colleagues from the Division of Cardiology, Tongji Hospital, as well as all the medical staff fighting against COVID-19, for their tremendous efforts. 

This article is protected by copyright. All rights reserved 

ACEi or ARB before hospitalization; N=355, 30.0%) and the non-RAS inhibitors group (patients not taking ACEi or ARB, but on other anti-hypertensive medications before hospitalization, N=827, 70.0%). The comparison between the RAS inhibitors group and the non-RAS inhibitors group was the main analysis of the study. Among the RAS inhibitors group, 289 (81.4%) patients were treated with ARB and 66 (18.6%) individuals with ACEi. Comparisons between patients on angiotensin receptor blockers (ARB, N=289), and patients on angiotensin converting enzyme inhibitors (ACEi, N=66) vs. patients non-taking RAS inhibitors were sub-analyzed. Figure S2 . Study selection diagram for the meta-analysis.